title: PET/CT with (124)I-cG250: great potential and some open questions.
abstract: OBJECTIVE
  A novel PET radiotracer, (124)I-cG250, is currently under clinical investigation to distinguish clear cell renal cell carcinoma from other benign and malignant renal masses. In this article, we will make suggestions on the data needed to maximize the use of this radiotracer.
  
  
  CONCLUSIONS
  Although the published data are promising, further data are needed to assess the potential usefulness of this agent when dealing with indeterminate renal masses.
authors: 1 Department of Radiology, Division of Nuclear Medicine, University of North Carolina School of Medicine, CB#7510, Chapel Hill, NC 27599-7510.
authors: Amir H
authors: AH
authors: Khandani
authors: W Kimryn
authors: WK
authors: Rathmell
authors: Eric M
authors: EM
authors: Wallen
authors: Marija
authors: M
authors: Ivanovic
mesh_terms: D000911:Antibodies, Monoclonal; D002256:Carbonic Anhydrases / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007457:Iodine Radioisotopes; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D064847:Multimodal Imaging; D060787:Neoplasm Grading; D049268:Positron-Emission Tomography / Q000379:methods*; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; C106533:G250 monoclonal antibody; D007457:Iodine Radioisotopes; D002256:Carbonic Anhydrases
keywords: 124I-cG250 PET/CT; clear cell renal cell carcinoma; indeterminate renal masses